

The Immuron logo is located in the top right corner. It features the word "Immuron" in a blue, sans-serif font, with a stylized circular icon to the right of the text. The background of the entire slide is a blue-tinted anatomical illustration of a human torso, showing internal organs like the liver, stomach, and intestines in a semi-transparent, glowing manner.

Immuron

*A world leader in
orally delivered
Antibodies*

2014 INVESTOR PRESENTATION

**Chief Executive Officer
Amos Meltzer**

**ASIA
Biotech
Invest 2014**
Gateway to Asia's Life Science Investor Community

3 - 5 June 2014
Sheraton Hotel & Towers
Hong Kong
www.AsiaBiotechInvest.com

Forward-looking Statement


Certain statements made in this presentation are forward-looking statements and are based on Immuron's current expectations, estimates and projections. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended to identify forward-looking statements.

Although Immuron believes the forward-looking statements are based on reasonable assumptions, they are subject to certain risks and uncertainties, some of which are beyond Immuron's control, including those risks or uncertainties inherent in the process of both developing and commercializing technology. As a result, actual results could materially differ from those expressed or forecasted in the forward-looking statements.

The forward-looking statements made in this presentation relate only to events as of the date on which the statements are made. Immuron will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this presentation except as required by law or by any appropriate regulatory authority.

What do we do?

- ✓ A revenue generating product for preventing traveller's diarrhoea
- ✓ A Phase II clinical product for treating liver disease – an unmet medical need
- ✓ Targeting the human immune system with natural antibodies derived from bovine colostrum to address diseases of the gut and liver



The Immuron Pipeline



Unique Platform Technology

- ✓ Attractive risk-reward ratio – biotech upside with reduced risk profile

Immuron's Platform Products	Other Products
✓ Natural product	✗ Synthetic product
✓ Rapid Development Cycle	✗ Longer and substantially more costly development
✓ Not a binary outcome. ✓ If clinical end points not attained, there is still a product that generates revenue	✗ Binary outcome: clinical trial failure means there is no product
✓ Does not suppress immunity	✗ Can suppress immunity
✓ Polyclonal Abs combat infectious diseases effectively	✗ Monoclonal Abs are strain specific
✓ Multiple regulatory pathways	✗ Ordinarily: one regulatory pathway

Corporate Structure

Capital Structure

ASX Code: IMC

Securities Currently on Issue

Shares

2,985,424,712

Listed Options

115,995,306*

Unlisted Options

253,445,219*

Market Cap (AUD)

~\$15M

Share Price (AUD)

0.5 cents

** Note: 337,694,494 of options listed above are exercisable at more than a 100% premium to current share price.*

Board and Management

Dr Roger Aston
Chairman

More than 20 years of experience in the pharmaceutical and biotech industries. He was the Founding CEO Chief Executive Officer and a Director of Mayne Pharma Group Limited.

Daniel Pollock
Non-executive Director

Internationally experienced lawyer admitted in both Scotland and Australia, with significant commercial expertise in new market entries into overseas markets, distribution agreements and corporate start-ups.

Stephen Anastasiou
Non-executive Director

Extensive experience in general management, marketing and strategic planning in the healthcare industry, formerly with KPMG.

Amos Meltzer
Chief Executive Officer

Over 20 years of technology commercialization experience across a diverse range of businesses primarily in the life sciences. He served in-house legal and commercialization roles with two Nasdaq-listed companies, most recently, Compugen Limited.

Mark Sullivan
Clinical Director

Over 20 years experience in the development of therapeutics including with Glaxo (now GSK) and Gilead Sciences.

Dr. Yaron Ilan
Medical Officer

Director-Inpatient Medicine Department at Hadassah Medical Center. He holds more than 50 patents and co-authored more than 240 articles.

Nicky Konstantopolous
Development Manager

Experienced scientist with expertise in insulin action and metabolic conditions. She has held postdoctoral roles with the Joslin Diabetes Centre at Harvard Medical School (Boston) and CSIRO (Parkville, Melbourne).


Reza Moussakhani
Manufacturing Quality Director

A professional Operations manager with extensive experience in implementation of project / quality and process improvements including with Hospira and Sigma Pharmaceuticals.

The Immuron logo is located in the top right corner. It consists of the word "Immuron" in a blue, sans-serif font, followed by a circular icon containing a stylized white 'e' shape.

Immuron

2.
TRAVELAN®
*Stop diarrhoea
BEFORE it starts*



OVERVIEW

TRAVELAN

NASH

C. DIFF

SUMMARY

Immuron

Travelan®

- Traveller's diarrhoea market estimated between US\$600M and 1.2B globally
- All-natural product; clinically proven science with very high safety profile
- Available over-the-counter



Unique: The only oral therapy which prevents travellers' diarrhoea

Without Travelan®

Bacteria releasing diarrhoea-causing toxins in gut



With Travelan®

Bacteria neutralised by Travelan® antibodies



Travelan®

Increasing sales; improved margins



Sales through pharmacies



Sales & marketing to doctors



Online sales

OVERVIEW

TRAVELAN

NASH

C. DIFF

SUMMARY

Immuron

Travelan®


Successful Australian brand, now going global



The background of the slide is a blue-tinted anatomical illustration of a human torso. The liver is highlighted in a bright red and yellow color, indicating inflammation or fatty liver disease. The rest of the body, including the lungs, stomach, and intestines, is shown in a translucent blue. The text "3. NASH / ASH (INFLAMED FATTY LIVER)" is overlaid on the left side of the image.

3.
NASH / ASH
(INFLAMED
FATTY LIVER)

NASH (NonAlcoholic SteatoHepatitis) & ASH (Alcoholic SteatoHepatitis)



NASH or inflamed fatty liver refers to a spectrum of chronic liver diseases

- Closely associated with obesity, diabetes and high cholesterol



ASH is caused by excessive alcohol consumption

- Poor prognosis leading to jaundice and liver failure



Currently no approved drug on market

OVERVIEW

TRAVELAN

NASH

C. DIFF

SUMMARY

Immuron

IMM-124E for NASH

How Big is the Opportunity?

→ Estimate: Off-label market ~\$2B and growing

→ NCID predicts:
>25M Americans will have NASH by 2025

→ **What this means for Immuron:**

- There is a huge, unmet opportunity
- NASH on the radar
- Immuron may be best in class

Intercept Pharmaceuticals

(NASDAQ: ICPT) \$1.5B before more than quadrupling overnight on NASH trial results

Illustration:



[OVERVIEW](#)[TRAVELAN](#)[NASH/ASH](#)[C. DIFF](#)[SUMMARY](#)

IMM-124E: Solution for NASH & ASH

The same disease caused by different causes

IMM-124E Addresses the cause of NASH and ASH and is safe

May be best in class

NASH

The very large commercial opportunity

IND cleared by FDA

First clinical trials completed for NASH:
very encouraging results

Phase II trials to commence later this year

ASH

Results from this trial expected to augment
NASH data package

IND cleared by FDA

Phase II trials to commence later this year

NIH funded, selected as 1 of 3 (from a possible
27) treatments to be funded by the NIH


The Immuron logo is located in the top right corner. It consists of the word "Immuron" in a blue, sans-serif font, followed by a circular icon containing a stylized white 'e' shape.

Immuron

4.

C. DIFF

*Treatment for
Superbug infections*



Treatment for superbug infections


- IMM-529 as therapy for infections due to overuse of antibiotics
- Clostridium difficile (C.diff): a gut-borne bacteria
 - superbug
 - more than US\$3.2 billion in health care costs each year in the United States
- IMM-529 under collaboration with Monash University
- Positive pre-clinical results to date

US Hospitalisations Skyrocket Annually due to C.diff



Source:
Agency for Healthcare Research and Quality

5. INVESTMENT SUMMARY



Exciting upside underpinned by growing revenues

- 1 Travelan®
 - Sales growing and set to accelerate
 - Revenue generating in Australia
 - Global expansion of Travelan® underway


- 2 Fatty liver/ NASH
 - Large unmet medical need
 - Increasing investor and partnering focus
 - Phase I/IIa completed
 - IND cleared by FDA for Phase IIb commencing this year

- 3 Rich Product Pipeline
 - Compelling Mechanism of Action
 - Applications to NASH, ASH and C.diff

- 4 Unique low-risk platform technology with marketable products at multiple inflection points

- 5 Strong balance sheet

Targeting the human immune system with natural antibodies derived from bovine colostrum to address diseases of the gut and liver

The background of the slide features a blue-tinted illustration of a human torso. The internal organs, including the lungs, liver, stomach, and a detailed view of the large and small intestines, are highlighted in a warm, glowing orange-red color. The Immuron logo is positioned in the upper right corner.

Immuron

THANK YOU

By Chief Executive Officer
Amos Meltzer
ameltzer@immuron.com